Lamictal Tablets, Lamictal Chewable Dispersible Tablets, and Lamictal ODT Orally Disintegrating Tablets all can cause serious rashes that can cause hospitalization. The chance of these rash incidents are 8 per 1,000 in 2 to 16 year old pediatric patients and 3 per 1,000 in adults receiving adjunctive therapy for epilepsy. Almost all of the critical rashes caused by Lamictal occurred within 2 to 8 weeks of the initiation of treatment. Isolated cases have taken place after prolonged treatment however. It is not possible to reliably predict which rashes are life-threatening so Lamictal should be discontinued at the first sign of a rash unless the rash is positively not a drug-related rash.
Lamictal is lamotrigine which is a phenyltriazine class AED. Lamotrigine is unrelated chemically to existing AEDs and is a powder that is white or pale cream colored.
Lamictal Tablets are for oral administration and come in:
The labeled amount of lamotrigine is contained in each tablet as well as the following inactive ingredients:
Yellow Ferric oxide (only 150mg tablets)
FD&C Yellow #6 Lake(only 100mg tablets)
FD&C Blue #2 Lake (only 200mg tablets)
Lamictal Chewable Dispersible Tablets are for oral administration and the following amounts of lamotrigine:
The Lamictal Chewable Dispersible tablets contain the labeled amount of lamotrigine and the following inactive ingredients:
magnesium aluminum silicate
sodium starch glycolate
Lamictal ODT Orally Disintegrating Tablets are for oral administration and contain the following amounts of lamotrigine:
White or off-white-25mg
White or off-white-50mg
White or off-white-100mg
White or off-white-200mg
Lamictal ODT Orally Disintegrating contains the labeled amount of lamotrgine and the following inactive ingredients:
artificial cherry flavor
Formulated using Microcaps ® and AdvaTab ® technologies designed to mask lamotrigine’s bitter taste and dissolve tablets rapidly LAMICTAL ODT Orally Disintegrating Tablets were rated favorable for ease of use.
Lamictal is use for the following:
Lamictal is used in patients older than 2 years for the Ajunctive therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized sezures of Lennox-Gastaut syndrome.
Lamictal is also used for patients 16 years of age or older for the conversion to monotherapy in adults with partial seizures who are receiving current treatment with carbamazepine, Phenobarbital, Phenobarbital, or valproate as the single antiepileptic drug (AED). Lamictal’s effectiveness and safety have not been established yet as initial monotherapy or for the conversion to monotherapy form antepileptic drugs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate. Lamictal’s safety and effectiveness also has not yet been established for simultaneous conversion to monotherapy from two or more concomitant antepileptic drugs.
Another use for Lamictal in adults is for the maintenance treatment of Bipolar l Disorder to delay mood episodes such as mixed episodes, depression, mania, and hypomania.